KRAS and ovarian neoplasm: Certain mutations seem to play an important role in BOTS without the BRAF V600E variant (KRAS) and in lgOvCa (KRAS and NRAS), but not in hgOvCa, once again proving that advanced OvCa are molecularly distinct from less aggressive ovarian neoplasms.